SAN DIEGO, Calif.–(BUSINESS WIRE)–Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 SABCS
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
